RxDoctor Payments Data

Zulehuma Rather, MD

Internal Medicine · Dover, DENPI 1386966083

Payments from drug & device makers

$665in general payments, 2019–2025

Across 47 payments — averaging $14.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$257
  • Lilly USA, LLC$110
  • AstraZeneca$102
  • Boehringer Ingelheim$41
  • AbbVie$27
  • Dynavax Technologies Corporation$26
  • plus $101 from 6 others

What the payments were for

  • Food & beverage$65799%
  • Education$81%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$665 in reported general payments places this provider in the 75th percentile of 477 internal medicine providers in Delaware.

See all internal medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$93,881
Medicare patients
249
Services billed
1,066

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanumetSitagliptin Phos/Metformin Hcl12$16,390
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,558
Breo ElliptaFluticasone/Vilanterol12$4,664
NexiumEsomeprazole Magnesium13$3,607
Famotidine61$3,428
Rosuvastatin Calcium99$3,382
Albuterol Sulfate HfaAlbuterol Sulfate68$2,950
Advair DiskusFluticasone Propion/Salmeterol13$2,629
Atorvastatin Calcium205$2,439
Ezetimibe22$2,384
Omeprazole123$2,212
Levothyroxine Sodium144$1,875
Diclofenac Sodium30$1,776
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm12$1,714
Gabapentin101$1,701

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$14$17,22231 claims
AstraZenecaNexium$102$3,60713 claims
AbbVieSynthroid$27$79718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 477 internal medicine providers in Delaware.

Other internal medicine in Dover

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →